Eric Easom - Mar 15, 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Eric Easom
Stock symbol
ANTX
Transactions as of
Mar 15, 2024
Transactions value $
$0
Form type
4
Date filed
3/18/2024, 07:26 PM
Previous filing
Jan 4, 2024
Next filing
Nov 18, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +99K +4647.89% $0.00 101K Mar 15, 2024 Direct F1
holding ANTX Common Stock 1.02M Mar 15, 2024 See Footnote F2
holding ANTX Common Stock 97.1K Mar 15, 2024 See Footnote F3
holding ANTX Common Stock 97.1K Mar 15, 2024 See Footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +198K $0.00 198K Mar 15, 2024 Common Stock 198K $3.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
F2 Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
F3 Consists of shares of Common Stock held by the C Easom Irrevocable Trust dated October 8, 2021.
F4 Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
F5 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.